FNY Partners Fund’s AstraZeneca AZN Stock Holding History

FNY Partners Fund’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-250	Closed	-$17K	–	561
2017 Q2	$17K	Buy	+250	New	+$16.3K	﹤0.01%	356

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FNY Partners Fund's AZN Position: Q3 2017 in Review

FNY Partners Fund sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 250 shares — an estimated $17K sold.

FNY Partners Fund first reported a position in AZN in Q2 2017 and held it in 1 quarter. The position peaked at $17K in Q2 2017. 455 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

FNY Partners Fund reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
FNY Partners Fund sold 250 AstraZeneca shares in Q3 2017, an estimated $17K.
FNY Partners Fund first reported a position in AstraZeneca in Q2 2017 and held it in 1 quarter.
FNY Partners Fund's AstraZeneca position peaked at $17K in Q2 2017.
455 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.